These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20654586)

  • 1. Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
    Ishiguro K; Zhu YL; Shyam K; Penketh PG; Baumann RP; Sartorelli AC
    Biochem Pharmacol; 2010 Nov; 80(9):1317-25. PubMed ID: 20654586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.
    Baumann RP; Ishiguro K; Penketh PG; Shyam K; Zhu R; Sartorelli AC
    Biochem Pharmacol; 2011 May; 81(10):1201-10. PubMed ID: 21396917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
    Ishiguro K; Shyam K; Penketh PG; Sartorelli AC
    Mol Cancer Ther; 2005 Nov; 4(11):1755-63. PubMed ID: 16275997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
    Liu L; Markowitz S; Gerson SL
    Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
    Wedge SR; Porteus JK; May BL; Newlands ES
    Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.
    Baumann RP; Shyam K; Penketh PG; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):288-95. PubMed ID: 14685775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.
    Griffin RJ; Arris CE; Bleasdale C; Boyle FT; Calvert AH; Curtin NJ; Dalby C; Kanugula S; Lembicz NK; Newell DR; Pegg AE; Golding BT
    J Med Chem; 2000 Nov; 43(22):4071-83. PubMed ID: 11063604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
    Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.
    Baumann RP; Penketh PG; Ishiguro K; Shyam K; Zhu YL; Sartorelli AC
    Biochem Pharmacol; 2010 Jun; 79(11):1553-61. PubMed ID: 20005211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents.
    Dolan ME; Norbeck L; Clyde C; Hora NK; Erickson LC; Pegg AE
    Carcinogenesis; 1989 Sep; 10(9):1613-9. PubMed ID: 2766456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
    Zhu R; Baumann RP; Patridge E; Penketh PG; Shyam K; Ishiguro K; Sartorelli AC
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1853-9. PubMed ID: 23395657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
    Fontijn D; Adema AD; Bhakat KK; Pinedo HM; Peters GJ; Boven E
    Mol Cancer Ther; 2007 Oct; 6(10):2807-15. PubMed ID: 17938272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
    Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
    Ishiguro K; Seow HA; Penketh PG; Shyam K; Sartorelli AC
    Mol Cancer Ther; 2006 Apr; 5(4):969-76. PubMed ID: 16648568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.
    Zhu R; Liu MC; Luo MZ; Penketh PG; Baumann RP; Shyam K; Sartorelli AC
    J Med Chem; 2011 Nov; 54(21):7720-8. PubMed ID: 21955333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.
    Penketh PG; Shyam K; Baumann RP; Remack JS; Brent TP; Sartorelli AC
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):279-87. PubMed ID: 14704831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine.
    Toft NJ; Sansom OJ; Brookes RA; Arends MJ; Wood M; Margison GP; Winton DJ; Clarke AR
    Carcinogenesis; 2000 Apr; 21(4):593-8. PubMed ID: 10753191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
    Loktionova NA; Pegg AE
    Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.